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ABSTRACT 
Regulatory T cells (Tregs) are emerging as a new cell-based therapy in solid organ 
transplantation. Adoptive transfer of Tregs was shown preclinically to protect from graft 
rejection, and the safety of Treg therapy has been demonstrated in clinical trials. Despite these 
successes, the in vivo distribution and persistence of adoptively transferred Tregs remained 
elusive which hampers clinical translation. Here, we isolated human Tregs using a GMP-
compatible protocol and lentivirally transduced them with the human sodium iodide symporter to 
render them traceable in vivo by radionuclide imaging. Engineered human Tregs were 
characterized for phenotype, survival, suppressive capacity, and reporter function. To study their 
trafficking behaviour, they were subsequently administered to humanized mice with human skin 
transplants. Traceable Tregs were quantified in skin grafts by non-invasive nanoSPECT/CT for 
up to 40 days and results validated ex vivo. Using this approach, we demonstrated that Treg 
trafficking to skin grafts was regulated by the presence of recipient Gr-1+ innate immune cells. 
We demonstrated the utility of radionuclide reporter gene afforded quantitative Treg in vivo 
tracking thereby addressing a fundamental need in Treg therapy development and offering 
clinically compatible methodology for future Treg therapy imaging in humans.  
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Adoptive cell transfer; cell tracking; human sodium iodide symporter; SPECT/CT imaging; 
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INTRODUCTION 1 
Regulatory T cells (Tregs) are immunosuppressive cells with a fundamental role in the 2 
maintenance of tolerance to self-antigen in vivo.1, 2 Tregs are characterized by a constitutively 3 
high expression of CD25 and the master transcription factor forkhead-box protein 3 (FOXP3). 4 
Mice deficient in Foxp3 exhibit systemic autoimmune disease and their Tregs have an impaired 5 
suppressive capacity in vitro.  6 
In transplantation, graft rejection is a detrimental process driven by alloreactive T cells that 7 
recognize donor major histocompatibility complex (MHC) antigens (alloantigens) via various 8 
pathways.3 In addition to maintaining tolerance to self-antigens, Tregs contribute to controlling 9 
responses to alloantigens, and a correlation between the proportion of Tregs within a transplanted 10 
organ (allograft) and graft survival has been observed.4-6 This has led to the pursuit of protocols 11 
designed to tip the balance between Tregs and Teffs in favour of Tregs to induce transplantation 12 
tolerance. One strategy to increase Treg numbers is the purification of Tregs from allograft 13 
recipients, expanding and potentially manipulating them in vitro before re-administration. In 14 
immunodeficient mice transplanted with human skin and reconstituted with PBMC, adoptive 15 
transfer of human in vitro expanded polyclonal Tregs significantly prolonged the survival of skin 16 
allografts.7, 8 Polyclonal Treg-based cell therapy approaches yielded early promising results for 17 
the prevention of graft-versus-host disease (GvHD), after allogeneic hematopoietic stem cell 18 
transplantation9, 10, and maintenance of C-peptide levels in Type 1 diabetes.11, 12 We led two 19 
clinical phase I/II trials using adoptive transfer of polyclonal expanded Tregs to promote 20 
tolerance in kidney (ONE Study; NCT02129881) and liver (ThRIL; NCT02166177) transplant 21 
recipients.13-15 Resultant data suggested Treg therapy to be safe, well tolerated, and indicated 22 
some signs of efficacy. 23 
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Despite an increase in the numbers of clinical trials using human Treg therapy important 24 
questions pertaining to their in vivo fate, distribution and location of their function remain 25 
unclear. Recently, polyclonal Tregs labelled with [6,6-2H2]glucose were detected in the 26 
circulation of Type I diabetic patients for up to one year.12 However, it remains a challenge to 27 
identify adoptively transferred Tregs in tissues non-invasively.  28 
Non-invasive radionuclide imaging by single photon emission computed tomography 29 
(SPECT) or positron emission tomography (PET) offers excellent sensitivity with absolute 30 
quantification and true 3D information while being translatable to the clinic. Cell labelling 31 
approaches can either be direct or indirect with each approach offering distinct advantages and 32 
disadvantages.16 We previously showed that direct radiolabelling of murine CD4+ T cells, with 33 
99mTc-hexamethylpropyleneamine oxime, did not affect cell viability, but the radiolabelled cells 34 
could only be tracked for up to 24h due to the short radioisotope half-life of 99mTc (6.0h).17 This 35 
enabled the assessment of Treg biodistribution within a day after administration, but precluded 36 
desired long-term tracking of Tregs, which would require longer half-life radioisotopes. Longer 37 
half-life radioisotopes are available (e.g. 111In, 89Zr) but elicit also more radioactive dose18 38 
thereby limiting the study length. Using various T lymphocytes, recent studies involved tracking 39 
of about one week but not longer.19-21 In the context of transplant immunology, aiming to track 40 
Tregs to transplants, one week represents a short observation time, and significantly longer cell 41 
tracking would be beneficial.  42 
Long-term cell tracking can be achieved through indirect cell labelling, which involves 43 
genetic engineering to express a reporter and thereby render the cells in vivo traceable by repeat 44 
imaging.16, 22 Treg in vivo dynamics was assessed using bioluminescence approaches.23-25 45 
However, bioluminescence imaging is not translatable to the clinic because of the non-human 46 
nature of luciferases, which also require luminogenic substrate administration, and the added 47 
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disadvantages of optical imaging at depth (absorption, scatter) precluding reliable quantification. 48 
Radionuclide reporter genes present an alternative that enables 3D tomographic imaging and it 49 
has also been shown to be clinically translatable.26 Host reporter genes are from the same species 50 
as cell tracking should occur in and should be endogenously expressed in only a very limited 51 
number of host tissues to ensure favourable contrast and overcome any immunogenicity issues 52 
intrinsic to foreign reporters.16, 22 One of the most promising host reporter genes is the human 53 
sodium iodide symporter (NIS), which has been shown to be well tolerated in different cell types 54 
including cancer cells, cardiomyocytes, stem cells and T cells.27-30 In a proof-of-principle study 55 
employing retroviral transduction methodology, we demonstrated ex vivo engineering of murine 56 
Tregs to express NIS and detected the cells in vivo 24h post administration by SPECT imaging.31 57 
Importantly, it was recently also shown that the radioactivity levels which can be expected to be 58 
taken up into T cells through NIS use during imaging, did not cause lasting DNA damage in T 59 
cells.32 Moreover, the matching radiotracers required for NIS imaging have already been 60 
translated to humans (for thyroid imaging).33, 34 Together, these features render NIS a well-61 
established reporter gene suitable for preclinical long-term cell tracking and a candidate reporter 62 
for the clinical setting. Notably, so far long-term in vivo tracking of human Tregs has not been 63 
addressed using a reporter gene imaging approach that can be translated to the clinic. 64 
Our goal was to genetically engineer GMP-isolated and in vitro expanded human Tregs, 65 
characterize the resultant traceable Tregs, and apply them to investigate their capacity to home to 66 
and reside within human skin transplants in a humanized mouse model. As it was reported that 67 
during inflammation soluble mediators, for example chemokines produced by infiltrating 68 
granulocytes and monocytes, were critical for the recruitment of adaptive immune cells to 69 
antigen-rich tissues35, we applied our approach to investigate whether innate immune cells had 70 
an effect on Treg trafficking to skin grafts.  71 
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RESULTS 75 
Generation of in vivo traceable Tregs 76 
CD4+CD25high Tregs from donor blood were enriched using GMP protocols13-15 and stimulated 77 
with anti-CD3/CD28 beads in the presence of rapamycin and IL-2 (Fig.S1). Three days after 78 
stimulation, Tregs were transduced with lentiviral particles transferring DNA encoding the 79 
radionuclide-fluorescence fusion reporter gene NIS-GFP (Fig.1A; monomeric GFP aides 80 
traceable Treg generation, purification and ex vivo detection27, 28, 36). Transduced NIS-GFP+ 81 
Tregs were purified by cell sorting (purity>99%; Fig.1B), and NIS-GFP was found 82 
predominantly in the plasma membrane suggesting correct intracellular reporter trafficking 83 
(Fig.1C). No significant changes in reporter expression levels were observed over six weeks 84 
suggesting stable NIS-GFP expression (Fig.1D). Importantly, we also did not find differences in 85 
Treg expansion between untransduced and reporter expressing Tregs (Fig.1E). NIS-GFP+ Tregs 86 
showed uptake of the radioactive NIS substrate 99mTcO4- while untransduced Tregs did not 87 
(Fig.1F). [99mTc]TcO4- uptake was also significantly reduced in NIS-GFP+ Tregs in the presence 88 
of excess amounts of the NIS co-substrate perchlorate, thereby demonstrating radiotracer uptake 89 
to be specific for NIS-GFP expression (Fig.1F).  90 
 91 
NIS-GFP+ Tregs maintain phenotype and function 92 
To investigate whether reporter transduction and radiolabelling impacted on the Treg phenotype, 93 
we compared NIS-GFP+ Tregs with un-transduced Tregs employing established Treg markers 94 
(CD25, FOXP3, CTLA-4). This comparison was performed with identical Treg batches that had 95 
either been exposed to [99mTc]TcO4- radiotracer or vehicle, and no significant impact of NIS 96 
transduction and NIS use (radiolabelling) was detected (Fig.2A/B, Fig.S2). Next, we assessed the 97 
suppressive capacity of NIS-GFP+ Tregs as compared to un-transduced Tregs based on their 98 
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ability to suppress the proliferation of dye-labelled effector T cells (Teff). No significant 99 
differences between NIS-GFP+ Tregs and un-transduced Tregs were found, neither in the 100 
presence nor in the absence of exposure to the NIS radiotracer [99mTc]TcO4- at different 101 
Teff:Treg ratios (Fig.2C, Fig.S3). Importantly, this data demonstrated that (i) NIS-GFP+ Tregs 102 
maintained their suppressive function after lentiviral transduction and upon stable reporter 103 
expression, and (ii) the amount of [99mTc]TcO4- used, which is comparable to what NIS-104 
GFP+ Tregs would experience upon reporter gene imaging in vivo, did also not impair their 105 
function.  106 
Taken together this data showed that human Tregs genetically engineered via lentiviral 107 
transduction technology to stably express the radionuclide-fluorescence reporter NIS-GFP 108 
maintained their phenotype and suppressive function following labelling.  109 
 110 
In vivo detection of NIS-GFP+ Tregs in a humanized mouse model 111 
First, we assessed the detection sensitivity of [99mTc]TcO4--labelled NIS-GFP+ Tregs in our 112 
nanoSPECT/CT instrument and found a limit of detection (LOD) of ~10,000 NIS-GFP+ Tregs 113 
per million of untransduced cells (Fig.S4). This data demonstrated the feasibility of Treg 114 
tracking by NIS reporter gene imaging. 115 
Next, we determined traceability of NIS-GFP+ Tregs in vivo in a well-established human 116 
skin xenograft transplant model. We previously had demonstrated the efficacy of human 117 
polyclonal Tregs to reduce alloimmune human skin injury (30 days post administration).7, 12 118 
Therefore, human skin grafts were prepared using immunocompromised BALB/c recombination 119 
activating gene 2-/-γc-/- (BRG) mice as recipients. Six to seven weeks after skin engraftment, 120 
transplant-bearing mice were randomized, and allogeneic CD25-depleted PBMCs were 121 
intravenously administered, either alone or together with NIS-GFP+ Tregs. Importantly, murine 122 
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granulocyte receptor 1 (Gr-1)-positive cells including neutrophils and certain monocytes were 123 
still functional in BRG mice. To achieve a higher level of immunocompromisation, Gr-1+ cells 124 
were depleted using an antibody raised against Gr-1 as previously described (see scheme in 125 
Fig.3A and 7, 12, 37). It is noteworthy that despite this being an established approach to deplete 126 
remaining Gr-1+ cell using the indicated antibody, we confirmed its success by histology 127 
(Fig.S5). Treg in vivo detection was based on the visualization of NIS-GFP+ Tregs by SPECT 128 
imaging with the NIS radiotracer [99mTc]TcO4-. Notably, the host reporter gene human NIS is 129 
homologous to murine NIS (mNIS) and the radiotracer detected both forms.38 This explained 130 
why we observed in mice that did not receive NIS-GFP+ Tregs (Fig.3C) the following signals 131 
attributed to endogenously expressed mNIS: thyroid, salivary and lachrymal glands, the stomach 132 
and, at lower levels, in the small intestine and the testes of male mice. Bladder signals were 133 
caused by the expected renal radiotracer excretion. Importantly, in animals that had received 134 
NIS-GFP+ Tregs, we detected the traceable therapeutic cells in the transplants (Fig.3D). 135 
Importantly, none of the aforementioned organs with endogenous mNIS expression or involved 136 
in renal radiotracer excretion contributed to any background signals in human skin grafts (cf. 137 
Fig.3C-D/insets) enabling the quantification of NIS-GFP+ Tregs in the skin grafts. 138 
 139 
Serial in vivo imaging revealed a role for Gr-1+ innate immune cells in Treg recruitment. 140 
Next, we used serial SPECT/CT imaging to track NIS-GFP+ Tregs at different time points after 141 
intravenous administration into transplant-bearing immunocompromised mice lacking Gr-1+ 142 
innate immune cells. BRG mice received traceable NIS-GFP+ Tregs and were treated with the 143 
anti-Gr-1 antibody to deplete this cell compartment (Fig.S5). We found that radiotracer uptake 144 
levels in their human skin grafts did not significantly differ from control animals (no NIS-145 
GFP+ Tregs and only CD25-depleted PBMCs administered) for the first two weeks (cf. pink vs. 146 
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black lines in Fig.4). Notably, NIS-GFP+ Treg presence was significantly elevated compared to 147 
control animals at late time points, ranging 30-40 days after administration (Fig.4). Using 148 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, which have less and mostly dysfunctional innate 149 
immune cells39 and thus did not receive the anti-Gr-1 antibody, we obtained similar results 150 
compared to those obtained in BRG mice with Gr-1+ cell depletion (Fig.S6). 151 
Next, to investigate the role played by Gr-1+ innate cells on Treg recruitment to skin 152 
grafts, we determined the in vivo trafficking behaviour of i.v. administered NIS-GFP+ Tregs in 153 
transplant-bearing BRG mice without anti-Gr-1 antibody administration (Fig.4 and Fig.S5). 154 
Interestingly, NIS-GFP+ Tregs were detectable at the skin grafts as early as three days after 155 
administration. Their signals peaked at around eight days and remained detectable in the 156 
transplants up to 40 days post administration (Fig.4C). Image quantification revealed significant 157 
differences between BRG mice without and with Gr-1+ cell depletion at the early time points 158 
after Treg administration (Fig.4D). The early trafficking of Tregs to the skin in the presence of 159 
Gr-1+ cells suggested an active role of these cells in influencing Treg recruitment to the graft. 160 
 161 
Ex vivo validation of in vivo imaging 162 
Animals of each cohort were sacrificed at the indicated time points and radioactivity in the graft 163 
tissues was quantified (by γ-counting). Human skin grafts were compared to mouse skin from the 164 
same animal using paired analyses. In control animals that did not receive traceable Tregs, no 165 
significant differences in tissue radioactivity between human grafts and mouse skins at any time 166 
point were observed (Fig.5A; solid vs. dashed black lines) demonstrating no human graft-specific 167 
radiotracer accumulation. In BRG mice that had also received anti-Gr-1 antibody treatment, we 168 
observed no significant differences between human and mouse tissues for the first two weeks but 169 
identified a significant difference between the two skins types on day 40 (p=0.0309; Fig.5A: 170 
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compare solid vs. dashed pink lines). Importantly, in BRG mice with Gr-1+ cells present, the 171 
radioactivity found in human skin grafts was higher than in mouse skin at all time points 172 
(p=0.0016; Fig.5A; solid vs. dashed blue lines). These comparisons of human skin grafts with 173 
mouse skin from the same animals clearly demonstrated a preference for traceable human Tregs 174 
to accumulate at human skin grafts. 175 
Human skin grafts from different animal cohorts were compared using unpaired statistical 176 
analysis. The radioactivity levels in human skin grafts on day 8 were significantly higher in BRG 177 
mice with Gr-1+ cells present compared to BRG mice lacking Gr-1+ cells and control cohorts 178 
(Fig.5A). Notably, there were no differences between the mouse skins of the same three animal 179 
cohorts. On day 40, the situation had changed with both experimental cohorts (BRG with Gr-1+ 180 
cells and BRG without Gr-1+ cells) showing significantly elevated radioactivity in human skin 181 
grafts compared to control animals (p=0.0340 and p=0.0071, respectively; Fig.5A; ANOVA with 182 
Holm-Sidak multiple comparison correction). This data further confirmed our in vivo imaging 183 
data.  184 
Moreover, we used immunofluorescence histology to independently validate NIS-185 
GFP+ Treg presence in human skin grafts. First, in control animals that had received only CD25-186 
depleted human PBMCs, we found human CD3+ (Fig.5B), while in additional control mice that 187 
had only received saline, we did not observe the presence of any human CD3+ cells (Fig.5C). In 188 
BRG mice that were treated with the anti-Gr-1 antibody, we detected human CD3+FOXP3+ 189 
Tregs alongside human CD3+ in the skin grafts on day 40 (Fig.5D). Importantly, we also found 190 
human CD3+FOXP3+ Tregs in the human skin grafts of BRG mice with Gr-1+ cells present both 191 
on day 8 and day 40 (Fig.5E-F), again confirming our previous results. We also obtained ex vivo 192 
results in line with in vivo imaging data for NSG mice (Fig.S5D-E). 193 
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In summary, our in vivo imaging data was confirmed by two independent ex vivo tissue 194 
analyses and demonstrated murine Gr-1+ cells to affect human Treg arrival in human skin graft 195 
models.  196 
 197 
Human Treg migration is enhanced by murine neutrophils/monocytes in vitro 198 
To gain more mechanistic insight into the role of innate immune cells on Treg recruitment, we 199 
tested whether murine neutrophils and/or monocytes could affect human Treg migration using in 200 
vitro transmigration assays.  201 
First, we analysed whether human Tregs responded to the murine chemokines 202 
CCL17/CCL22. It has previously been reported that Tregs are responsive to gradients of 203 
chemokines engaging CCR440, 41, and we confirmed here that human Tregs expanded in vitro 204 
according to our GMP protocol continued to express high levels of CCR4 (Fig.S7). The same 205 
human Treg preparations used for in vivo tracking experiments (see Fig.S8A for individual 206 
donors) were seeded into the top well of a transwell system and their migration through a 3 µm 207 
porous membrane was quantified with the bottom chamber containing media with the indicated 208 
admixtures. In some conditions, Tregs were pre-treated with pertussis toxin (PTX). The murine 209 
chemokines CCL17/CCL22 were able to increase human Treg migration (p<0.0001; 2-way 210 
ANOVA), an effect that was reverted by PTX pre-treatment of Tregs (Fig.6A-B) thereby 211 
suggesting G-protein-coupled receptor (GPCR) involvement. 212 
Having established that human Tregs responded to murine pro-migratory stimuli, we then 213 
investigated whether isolated murine neutrophils and/or monocytes (Fig.S8B-C) could induce 214 
human Treg migration. To exclude any direct cell-cell interactions, neutrophils/monocytes were 215 
provided in the bottom chambers while human Tregs were added to the top well of the transwell 216 
system. Notably, both neutrophils and monocytes were activated in this experiment due to the 217 
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use of zymosan during their preparation (see Materials and Methods). Both neutrophils and 218 
monocytes as well as their combination significantly increased human Treg migration (Fig.6C-D; 219 
p=0.0112; 2-way ANOVA). A synergistic effect of both neutrophils and monocytes was not 220 
observed. Notably, the enhancement of human Treg motility was reduced when they were pre-221 
treated with PTX with then no significant migration differences detected between the presence, 222 
or absence, of the indicated cell types (Fig.6E-F; p=0.2478; 2-way ANOVA). 223 
Taken together, murine Gr-1+ cells accelerated human Treg recruitment to inflammatory 224 
sites (such as human skin graft models) by the production of GPCR ligands, likely chemokines, 225 
which cross-reacted with GPCRs on human Tregs.  226 
 227 
 228 
229 
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DISCUSSION 230 
We have previously demonstrated the efficacy of human polyclonal Tregs at reducing 231 
alloimmune injury in a human skin xenograft transplant model.7, 8 However, little was known 232 
about the in vivo distribution and fate of administered Tregs, and it remained extremely 233 
challenging to track adoptively transferred Tregs non-invasively in solid tissues. We have 234 
previously attempted to assess the in vivo distribution of murine Tregs by whole-body imaging 235 
within a day of administration.17, 31 What remained elusive was long-term tracking as well as 236 
tracking of human Tregs in skin transplant models to quantify their arrival at transplant sites.  237 
Therefore, we used the well-established dual-mode reporter NIS-GFP28 to enable long-term 238 
in vivo tracking. The Achilles heel of all reporter gene-afforded cell tracking is the additional 239 
regulatory hurdle upon clinical translation due to the need to genetically engineer the cell 240 
product. However, chimeric antigen receptor (CAR)-Treg therapy has recently been emerging as 241 
the next-generation strategy for Treg therapy. We, and others, have already successfully 242 
generated and characterized prototype CAR-Tregs for various indications including colitis, 243 
multiple sclerosis, and in humanized mouse models of xeno-GvHD and human skin 244 
transplantation.37, 42-44 We performed gene transfer into Tregs using lentiviral technology, which 245 
has been successfully used for genetic engineering of cell-based therapeutics in the clinic before 246 
(e.g. anti-cancer CAR T-cell therapeutics).45, 46 The first CAR Treg clinical trial has been granted 247 
by UK MHRA authorisation a phase I/II clinical trial (STEADFAST) for kidney transplant 248 
patients. Therefore, investigation of the suitability of reporter gene technology for therapeutic 249 
Tregs was worthwhile as it provided another mosaic piece in the journey to further develop and 250 
translate Treg/CAR-Treg therapy for human use. 251 
The most promising host reporters currently available for our purpose were NIS38 and 252 
PSMA47 (for a review on host reporter genes for immune cell tracking see16), neither of which 253 
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was expressed in human or mouse dermis or epidermis. NIS offered the local technical 254 
advantage of a generator-produced radiotracer ([99mTc]TcO4-) for SPECT imaging avoiding 255 
radiotracer synthesis on each imaging day. Preclinically the sensitivity advantages of PET over 256 
SPECT are not so pronounced on high-quality instrumentation, however, clinically PET is 257 
superior to SPECT in sensitivity. Importantly, a clinical PET tracer for NIS is already clinically 258 
available ([18F]BF4-;28, 33) and will be particularly useful in the future when combined with new 259 
total-body PET instrumentation that has been shown to offer further significant sensitivity 260 
improvements (i.e. 40-fold improvement of total-body PET over existing clinical PET48). 261 
Moreover, NIS was reported to be very sensitive to cell viability due to its dependence on the 262 
cellular Na+/K+ gradient38, therefore enabling reliable imaging of live cells only. The fluorescent 263 
co-reporter GFP in our fusion reporter NIS-GFP helped streamline generation of traceable cells 264 
for preclinical experimentation.27, 28, 36 Notably, NIS-fluorescent protein fusion reporters have 265 
previously been shown (i) to be correctly localized to the plasma membrane and function in 266 
several different cell types (rodent and human cancer cells20, 27, 29, 36, 49, human CAR-T cells50, 267 
hepatocyte-like cells29), and (ii) to mediate uptake of various substrates similarly to unmodified 268 
NIS (for similar relative substrate uptake of NIS substrates compare Fig.S9A,36, 51 with 38, 52; for 269 
comparative considerations relating to the NIS Michaelis-Menten constant for tetrahedral 270 
substrates see Fig.S9B). Importantly, while NIS-GFP was practical for preclinical 271 
experimentation, the removal of GFP will be required to render our Treg tracking approach fully 272 
compatible with the workflows required for human application. Consequently, selection 273 
conditions will need to change but suitable NIS antibodies or alternative selective expansion 274 
strategies53 are already available. 275 
One apparent shortcoming of radionuclide reporter gene imaging approaches is their 276 
limited spatial resolution (low millimetre range). This can be overcome by combining them with 277 
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technologies that provide routinely about an order of magnitude higher resolution and anatomical 278 
context, such as x-ray computed tomography (CT) or magnetic resonance imaging (MRI).54 As 279 
this generally leads to better interpretability of obtained co-registered images by combining the 280 
best of both worlds, we had also adopted a multi-modal SPECT-CT imaging approach 281 
throughout this work.  282 
In this work, we generated Tregs stably expressing NIS-GFP for a minimum of six weeks 283 
(Fig.1) while we did not detect any negative effect of lentiviral transduction neither on Treg 284 
expansion (Fig.1) nor on Treg phenotypes or suppressive function (Fig.2). Importantly, there was 285 
also no negative impact of radiolabelling NIS-GFP+ Tregs with the SPECT radiotracer 286 
[99mTc]TcO4- followed by full radioactivity decay (Fig.2) lending credibility to the overall 287 
reporter imaging strategy to be safe for long-term monitoring of Tregs (in line with previous 288 
observations that it was safe in effector T cells32). We found the limit of detection for NIS-289 
GFP+ Tregs in our instrument to be ~104 cells/million (Fig.S4) and thus roughly one order of 290 
magnitude lower than what we previously found for cancer cells27; we attributed this to the Tregs 291 
being about ~2-fold smaller in cell diameter (amounting to ~⅛ in volume, thus taking up at least 292 
8-fold less radiotracer per cell). In this setting, we were able to track NIS-GFP+ Tregs for 40 293 
days post administration, only limited in time by animal license regulations, and ex vivo data 294 
confirmed in vivo results (Fig.4-5). Future work will need to focus on more in-depth analysis of 295 
potential reporter gene effects and put emphasis on potential transcriptomic, proteomic and 296 
metabolomic changes. 297 
Previous work in mice, for example in an islet allograft model, demonstrated that Tregs 298 
migrated from the blood stream first to inflamed allografts and subsequently to draining lymph 299 
nodes.55, 56 The latter phenomenon was not detected in our studies, not because of limited 300 
detection sensitivity but due to the lack of functional lymph nodes in the immunocompromised 301 
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mice used in this humanized model. Several studies in cancer and pregnancy research have 302 
suggested roles for neutrophils or monocyte-derived suppressor cells (MDSC) in the induction 303 
and recruitment of Tregs to tumours.57-59 Notably, MDSC were first identified to play an 304 
important role in tolerance induction in a rat kidney transplant model.60 There are two MDSC 305 
subtypes, monocytic (M-) and polymorphonuclear/granulocytic (PMN/G-)MDSC, which show 306 
some phenotypic similarity to either monocytes or neutrophils, respectively, and both present 307 
with immune suppressive functions. Furthermore, adoptive transfer experiments with M-MDSC 308 
and PMN-MDSCs in a heart transplant model demonstrated a role for these MDSC in Treg 309 
expansion in the transplant and for prolonged allograft survival.61 Despite much research, not 310 
least in human transplantation where a positive correlation between MDSCs and Tregs was 311 
observed62, 63, the detailed mechanisms by which MDSCs induce Tregs still remain unclear. Treg 312 
migration to inflamed islet allografts was, however, found to depend on CCR2, CCR5 and, 313 
importantly, CCR4.55 Both neutrophils and MDSC produce the chemokines CCL17/CCL22 that 314 
are ligands for CCR4 (40;Fig.S7), and the expression of this chemokine receptor by Tregs was 315 
previously implicated in their migration to allografts.55 Furthermore, CCL17 has also been 316 
shown to be involved in neutrophil-mediated Treg recruitment to tumors.59 Gr-1+ murine innate 317 
immune cells comprise of neutrophils and subsets of monocytes and dendritic cells. A Gr-1+ 318 
monocyte subset was previously observed in a cardiac transplant model64 and Gr-1+ monocytes 319 
have also been shown to differentiate into tolerogenic dendritic cells that produced IL-10 and 320 
thereby induced Treg responses in vivo in tumours.65 We hypothesized that murine Gr-1+ cells 321 
might also affect Treg recruitment in human skin transplant models. In vivo tracking of NIS-322 
GFP+ Tregs in human skin transplant-bearing BRG mice that were either left untreated or 323 
depleted of Gr-1+ murine cells revealed significant differences in NIS-GFP+ Treg recruitment to 324 
the grafts (Fig.4-5). These results were supported by data from NSG mice (Fig.S6), which have 325 
Jo
ur
al 
Pr
e-p
ro
f
19 
 
reduced amounts of functional innate immune cells including Gr-1+ cells39, and corroborated by 326 
subsequent in vitro assays demonstrating enhanced migration of human Tregs towards Gr-1+ 327 
murine neutrophils and monocytes (Fig.6B). We further confirmed that human Tregs were 328 
responsive to murine CCL17/CCL22 (Fig.6A) and our results are in line with previous data.66 329 
Our finding that murine Gr-1+ cell depletion resulted in delayed Treg detection at the human 330 
transplant (~3-4 weeks delay; Fig.4-5) further suggested a major role for the CCR4-331 
CCL17/CCL22 axis and warrants future investigations. Although the use of human Tregs in mice 332 
could have been a limitation in understanding the migration of human Tregs, our results have 333 
further demonstrated that human Tregs are attracted in vitro and in vivo by murine Gr-1+ cells. 334 
Notably, the work presented here in the context of transplantation suggests that for Tregs that 335 
lack antigen specificity the speed of migration to the transplant is controlled by the level of 336 
inflammation. In contrast, if Tregs present with donor-specificity, then their speed of migration is 337 
dictated by the recognition of the donor antigen on endothelial cells, and they have been shown 338 
to migrate to the respective skin graft within a week even in the absence of innate immune 339 
cells.25, 37 This is in agreement with the important role of antigen recognition on endothelial cells 340 
for the recruitment of T cells into tissue that was previously reported.67 Recently, we have 341 
extended this observation to CAR expressing Tregs in the same humanised mouse model 342 
described in this study. Recognition of HLA-A2 by A2-specific CAR-Tregs favoured the 343 
migration of these cells to the human skin.37 344 
The results of our study demonstrate that NIS is a suitable radionuclide reporter gene for 345 
non-invasive long-term tracking of Tregs. The Treg therapy field is currently moving towards 346 
CAR-Tregs, not least supported by several newly formed companies concerned with CAR 347 
development and optimization specifically for CAR-Treg therapy. Importantly, like for anti-348 
cancer CAR-T in solid tumours, there is also a requirement to monitor (CAR-)Treg distribution 349 
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and fate in therapy recipients. Here, we provide preclinical proof-of-principle to support the 350 
translation of long-term tracking of (CAR-)Tregs for future clinical application. Our 351 
methodology is well suited to support future CAR-Treg tracking work, as it relies on genetic 352 
engineering which is a prerequisite for CAR-Treg therapy and therefore no major additional 353 
regulatory burden is added to enable imaging/monitoring. Further steps on the path to clinical 354 
translation include, first, convincing others that the added cost of including imaging in trials is 355 
low compared to the production cost and value of this cell therapy type, and second, combining 356 
CAR and the NIS reporter into the same final vector for human cell therapy. Beside aspects 357 
relating to clinical translation of Treg therapy, our work provides a strategy to implement 358 
quantitative 3D tomographic imaging into the workflows of preclinical Treg therapy 359 
development, and not least, we contribute with our findings regarding the role of innate immune 360 
cells to the increasing understanding of human Treg migration to human skin grafts. 361 
 362 
 363 
364 
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MATERIALS AND METHODS 365 
Information regarding lentivirus production, flow cytometric marker analysis and fluorescence 366 
microscopy of cells, radiotracer uptake into cells, and determination of detection sensitivity of 367 
cells is detailed in Supplementary Information (SI). 368 
 369 
Ethical statement. The study involved human samples as well as animals. All procedures 370 
related to animal work were performed in accordance with all legal, ethical, and institutional 371 
requirements (PPL70/7302). Sample sizes of in vivo experiments were based on prior work from 372 
our laboratories27, 28, 37 and kept to a minimum in line with law and ethical guidelines for animal 373 
research in the UK as were the in vivo endpoints. Human skin and blood were obtained with 374 
ethical approval (Institutional Review Board ref# 09/H0707/86). Transplant-bearing animals 375 
were randomized before PBMC/Treg administration. 376 
 377 
Reagents. Standard reagents were from Corning, Merck, Sarstedt, Thermo-Fisher, TPP or VWR. 378 
[99mTc]TcO4- was generator-eluted as a sodium salt solution and used within 12h of elution.  379 
 380 
Animals. BALB/c recombination activating gene 2 (Rag2)-/-γc-/-(BRG; from A. Hayday, King’s 381 
College London) mice were bred at licensed in-house animal facilities. NOD.Cg-382 
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) and C57BL/6 mice were purchased from Charles River UK. All 383 
mice used were male and between 6 and 8 weeks old at the beginning of the experiment. Mice 384 
were maintained within the King’s College London Biological Services Unit under specific 385 
pathogen-free conditions in a dedicated and licensed air-conditioned animal room (at 23±2°C 386 
and 40-60% relative humidity) under light/dark cycles lasting 12h every day. They were kept in 387 
individually ventilated standard plastic cages (IVC; 501cm2 floor space; from Tecniplast) 388 
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including environmental enrichment and bedding material in the form of sterilized wood chips, 389 
paper stripes and one cardboard roll per cage. Maximum cage occupancy was five animals, and 390 
animals were moved to fresh cages with fresh environmental enrichment and bedding material 391 
twice per week. Sterilized tap water and food were available ad libitum; food was PicoLab 392 
Rodent Diet 20 (LabDiet) in the form of 2.5x1.6x1.0 cm oval pellets that were supplied at the top 393 
of the cages. For imaging, animals were anesthetized using isoflurane (1.5% (v/v) in pure O2). 394 
After imaging, mice were either left to recover from anaesthesia (by withdrawal of anaesthetic) 395 
in a pre-warmed chamber or sacrificed under anaesthesia by cervical dislocation. No adverse 396 
events were associated with the procedures performed in this study and animals put on weight in 397 
line with strain expectations (data from Charles River UK) throughout. Sentinel animals were 398 
kept on the same IVC racks as experimental animals and confirmed to be healthy after 399 
completion of the studies. 400 
 401 
Purification and culture of human PBMCs, Tregs and Teffs. Cells were isolated from 402 
peripheral blood donated by anonymous healthy volunteers via the National Blood Service with 403 
informed consent according to our GMP protocols13-15. Peripheral blood mononuclear cells 404 
(PBMCs) were separated by Lymphoprep density gradient centrifugation (PAA). CD4+ T cells 405 
were enriched using RosetteSep (StemCell Technologies) followed by selection and separation 406 
of CD4+CD25+ Tregs and CD4+CD25− Teffs using CD25 microbeads (Miltenyi). PBMCs were 407 
depleted of CD25+ cells also by using CD25 microbeads (Miltenyi) and from now referred to as 408 
CD25- PBMCs. Aliquots of CD25- PBMCs, Tregs and Teffs were cryopreserved in 5%(v/v) 409 
human serum (BioSera) containing 10%(v/v) DMSO. Tregs were activated with anti-CD3/CD28 410 
beads (1:1 bead:cell ratio; Miltenyi) and cultured in X-Vivo15 media (Lonza) supplemented with 411 
both 5%(v/v) human AB-serum (BioSera) (Treg medium) and 100nM rapamycin (LC-412 
Jo
urn
al 
Pr
e-p
roo
f
23 
 
Laboratories). 1000 U/mL recombinant human IL-2 (Proleukin-Novartis) was added 72h after 413 
cell isolation. After 10d, Tregs were activated with anti-CD3/CD28 beads (1:1 bead:cell ratio) 414 
for further expansion, which was repeated thereafter every 10d for expansion and longevity. X-415 
Vivo15 media supplemented with both human IL-2 and rapamycin (see above) was used to feed 416 
the cells every two days. Tregs were cultured at 37°C in the presence of 5%(v/v) CO2 in a 417 
humidified incubator. 418 
 419 
Generation of NIS-GFP expressing Tregs. Tregs (3d post isolation) were transduced with 420 
lentiviral particles transferring NIS-GFP as previously described.28, 37 Briefly, tissue culture 421 
plates were coated with 50 µg/µL retronectin (TakaraBio) overnight at 4°C before concentrated 422 
lentivirus particles and Tregs were added. Treg medium contained anti-CD3/CD28 beads, IL-2, 423 
and rapamycin. After 72h, virus containing medium was washed off and Tregs were maintained 424 
with fresh Treg medium every 48h for 7d until FACS sorting (BD FACSAria II, GFP channel). 425 
Post sorting NIS-GFP+ Tregs were re-stimulated in Treg medium containing anti-CD3/CD28 426 
beads, IL-2, and rapamycin. 427 
 428 
Suppression assay. 107 cells/mL HLA-A2-mismatched CD4+CD25− effector T cells were 429 
resuspended in staining solution containing 5 µM CellTrace Violet (CT-V) and incubated at 430 
37°C for 15 min prior to co-culture. Tregs and labelled Teffs were co-cultured in X-Vivo media 431 
at indicated ratios in the presence of anti-CD3/CD28 beads. Teff proliferation was assessed after 432 
5d by quantifying cellular CT-V using flow cytometry. Results are shown as %suppression 433 
(inverse of %Teff proliferation) relative to Teffs cultured alone. 434 
 435 
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Trans-well migration assay. Female 8-10 weeks old C57BL/6 mice received 1 mg/ml of 436 
zymosan i.p. and were culled 4 and 18h later to obtain neutrophils and monocytes from 437 
peritoneal cavities (via PBS washes), respectively. For monocytes, cells were left for 1h at 37°C 438 
in RPMI without serum allowing monocytes to adhere. Non-adherent cells were discarded. Cells 439 
were harvested, washed twice in cold PBS, counted, resuspended (RPMI containing 2%(v/v) 440 
FCS), and 3·105 cells/700 µL were plated per 24-well, forming the bottom wells of the migration 441 
assay. Some wells received admixtures of CCL17 and CCL22 (Peprotech; 1 ng/mL each).  442 
Human Tregs were isolated/purified as described above. Prior to plating, some Tregs were 443 
treated for 1h with 0.1 ng/mL pertussis toxin (PTX). Tregs were counted, resuspended at 3·105 444 
Tregs/300µL in Treg medium and added to the top of the trans-well chambers (3 µm pore size). 445 
The number of Tregs that migrated to the bottom chamber within 2h was counted while 446 
discriminating potentially present floating neutrophils or monocytes based on cell size. 447 
 448 
Human skin xenograft transplant model. Human skin was obtained from routine 449 
abdominoplasty with informed consent and ethical approval (ref# 06/Q0704/18). Donor HLA-450 
A2+ split thickness skin grafts were transplanted onto 10–12-week-old recipient BRG or NSG 451 
mice as previously described.7 Briefly, split-thickness (500-700µm) skin explants were harvested 452 
with a dermatome (Zimmer) and ~1.5cm2 pieces were transplanted into graft beds on indicated 453 
animals. Human skin grafts were fixed epidermal side upward onto similarly sized defects on 454 
recipient backs with an absorbable tissue seal (Vet-Bond, Braun Medical). Grafts were covered 455 
with Fucidin microbicide (Leo Laboratories Ltd.) and secured with Tegaderm film dressing (3M) 456 
for seven days, and skin was allowed to engraft for 40 days in total before initiation of 457 
experiments.  458 
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5-6 weeks after skin transplantation 5·106 PBMCs that were depleted of CD25+ cells (see above) 459 
were then administered i.v. together with or without 5·106 Tregs. No animals developed 460 
symptoms of xenogeneic Graft-versus-Host-Disease (GVHD), which was confirmed by 461 
maintenance of stable body weight. Skin grafts were subjected to visual and tactile inspection 462 
weekly for evidence of graft injury, and experiments ended 5 to 6 weeks after Teff transfer at 463 
latest. As indicated in experimental schemes, some BRG mice received 100 µg anti-mouse Gr-1 464 
(RB6-8C5, BioXCell; 1 mg/mL in saline) intraperitoneally every two days (Fig.3A).37 465 
 466 
In vivo imaging and image analysis. Mice were anesthetized with 2%(v/v) isoflurane/O2. 467 
SPECT/CT imaging was performed on animals that had received NIS-GFP+ Tregs. 20 MBq 468 
99mTcO4- (in 100 µL sterile PBS) was i.v. administered into anaesthetized animals and SPECT 469 
scans were acquired 40 min later (NanoScan SPECT/CT from Mediso equipped with high-470 
resolution multi-pinhole collimators for mouse imaging; 99mTc SPECT resolution ~0.6mm; CT 471 
resolution sub-100µm isotropic voxel). CT (55 kVp tube voltage, 1200 ms exposure time, 360 472 
projections) was performed after tracer administration but before SPECT. Repeat imaging with 473 
the same radiotracer was not affected by tracer amounts from prior imaging sessions.36 474 
SPECT/CT data were reconstructed using Tera-Tomo (Mediso) with corrections for 475 
attenuation, detector dead time, and radioisotope decay in place as needed. All images were 476 
analysed using VivoQuant software (inviCRO) enabling the delineation of regions of interest 477 
(ROIs) for quantification of activity. CT images were used to draw ROIs and provide the 478 
volumes required for standard uptake value calculations. The total activity in the whole animal 479 
(excluding the tail) at the time of tracer administration was defined as the injected dose (ID).  480 
 481 
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Ex vivo analyses of tissues. For analysis of radioactivity in harvested tissues, tissues were 482 
weighed, and radioactivity was quantified using a γ-counter (1282-Compugamma, LKB-Wallac), 483 
together with calibration standards. Data were expressed as %ID/g. 484 
Skin grafts were harvested alongside normal mouse skin of similar size (from lower back) 485 
for histology and frozen in OCT followed by tissue sectioning (8 µm). Thawed sections were 486 
fixed in 4% paraformaldehyde/PBS for 10 min, permeabilized (0.2%(v/v) Triton X-100/PBS), 487 
washed, and blocked (20%(v/v) goat serum/PBS containing 0.1% fish skin gelatine and 488 
0.25%(v/v) Tween-20) before being stained with the following primary antibodies (2 µg/mL) 489 
overnight at 4°C: anti-human CD3 (polyclonal rabbit; A0452, DAKO), anti-FOXP3 (monoclonal 490 
rat; clone PCH101; eBioscience), anti-Gr-1 (monoclonal rat; RB6-8C5; eBioscience) and anti-491 
GFP (monoclonal mouse; 3E6; Invitrogen). After washing, sections were then stained with 492 
secondary antibodies: goat anti-mouse-AlexaFluor555, anti-rabbit-AlexaFluor568 (Invitrogen) 493 
and anti-rat-Cy5 (Jackson Immunoresearch). Nuclei were stained with 4,6-diamidino-2-494 
phenylindole (DAPI; 10 µg/mL PBS). Samples were mounted using Fluorescence Mounting 495 
Medium (DAKO) and imaged on a NikonA1 confocal microscope. Fiji/ImageJ v1.5 software 496 
was used for analysis. 497 
 498 
Statistical analysis was performed using Prism v7 software (GraphPad) with details given in-499 
text and figure legends. Generally, the significance level α was set to 0.05.  500 
501 
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LIST OF FIGURE CAPTIONS 729 
 730 
Figure 1. Generation of Tregs stably expressing NIS-GFP. | (A) Sketch of the lentiviral 731 
construct; SFFV: spleen foci focus forming virus promoter. (B) Representative example of Treg 732 
transduction with the NIS-GFP reporter. Post-transduction FACS sorting yielded >99% pure 733 
NIS-GFP+ Tregs. (C) Fluorescence microscopy revealed NIS-GFP expression in Tregs to be 734 
predominantly membranous; scale bars=10 µm and 5 µm (inset). (D) Flow cytometric analysis of 735 
NIS-GFP+ Tregs in the weeks after transduction alongside corresponding untransduced Tregs 736 
(numbers indicate mean fluorescence intensities (MFI)); one representative of three experiments 737 
is shown. (E) Transduced NIS-FP+ Tregs were FACS sorted (cf. B) and further expanded for 738 
subsequent experiments over a period of 10 days. Fold-expansion of these cells during this 739 
period was quantified and compared to corresponding untransduced parental Tregs; box and 740 
whisker plot with median and 25th to 75th percentile indicated as well as min and max values 741 
drawn as whiskers; N=9, there was no significant difference between the cell types (F) NIS-GFP 742 
function as quantified per 99mTcO4- uptake in untransduced and NIS-GFP+ Tregs (grey). NaClO4 743 
block reporting on NIS-specificity (black); N=3, error bars=SD; ANOVA with Tukey multiple 744 
comparison correction. 745 
 746 
Figure 2. Assessment of marker expression and suppressive function. | (A-B) Treg markers 747 
CD25, FOXP3 and CTLA-4 were quantified by flow cytometry alongside CD4 (all via antibody 748 
staining) and NIS-GFP (via intrinsic GFP fluorescence). NIS-GFP+ Tregs were analysed by flow 749 
cytometry before and 6 d after 99mTcO4- uptake. Cumulative data describing (A) the percentage 750 
(B) and the mean fluorescence intensities; N=3, error bars are SD, Student’s t-test with Holm-751 
Sidak multiple-comparison correction. For representative individual data see Fig.S3. 752 
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(C) Comparison of suppressive capacity of untransduced and NIS-GFP+ Tregs with or without 753 
radiotracer treatment. Cumulative data of N=3 different Treg batches (donors); error bars are SD. 754 
No significant differences between cells with or without radiotracer treatment (Student’s t-test; 755 
untransduced Tregs: P1:1=0.3739; P1:3=0.2508; P1:10=0.3139; NIS-GFP+ Tregs: P1:1=0.3739; 756 
P1:3=0.1012; P1:10=0.1194). For representative individual data see Fig.S3. 757 
 758 
Figure 3. In vivo detection of NIS-GFP+ Tregs in human skin grafts. | (A) Experimental 759 
scheme including imaging conditions (radiotracer and time between its administration and 760 
SPECT imaging). (B) Representative example of a human skin transplant atop the spine of a 761 
BRG mouse on the day of adoptive immune cell transfer. All animals in this experiment (N=3 in 762 
each group) received the same human skin and Tregs from the same donor; all mice were 763 
depleted of Gr-1+ innate immune cells. (C-D) Sagittal sections of SPECT/CT images from 764 
representative animals that received 5·106 CD25-depleted PBMC but (C) no NIS-GFP+ Tregs or 765 
(D) 5·106 NIS-GFP+ Tregs 30 days prior to imaging. Overlays of SPECT images in hue (and on 766 
the same scale) with co-registered CT images (grayscale) are shown. Purple frames indicate 767 
magnified areas in different planes with the human skin graft circumscribed by dark yellow 768 
dotted lines; thin red crosshair lines indicate how indicated sections connect to one another. 769 
Endogenous (murine) mNIS expressing organs are visible in both groups and include 770 
thyroid/salivary glands (T/S), stomach (S), small intestine (Int)38, whereas bladder (Bl) signals 771 
are caused by radiotracer excretion. Images demonstrate (C) that the transplant area atop the 772 
spine remains free of any SPECT signals when no NIS-GFP+ Tregs were administered, and 773 
(D) that administered NIS-GFP+ Tregs were detected by SPECT imaging at the skin graft as they 774 
trafficked to this site over time.  775 
 776 
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Figure 4. In vivo tracking of NIS-GFP+ Treg arrival at human skin grafts. | (A) 777 
Experimental scheme; purple=human skin graft, green syringe=5·106 NIS-GFP+ Treg, black 778 
syringe=5·106 PBMCs; cohorts randomized upon adoptive cell transfer. (B/C) Longitudinal 779 
SPECT/CT images of transplant-bearing animals at indicated time points post adoptive cell 780 
transfer. Images acquired 40 min after 99mTcO4- administration (20 MBq). Side-view maximum 781 
intensity projections (top row) and coronal sections through the graft (bottom row) are shown; all 782 
images are on the same scale. Radioactive signals above background in grafts indicate NIS-783 
GFP+ Treg presence. Representative images from the same animal. (D) Cumulative quantitative 784 
analysis of in vivo imaging data; SUV=standard uptake value. Black dashed/dotted lines 785 
represent mean±SD of pooled control animals (PBMCs/no Tregs and no adoptive transfer; N=5). 786 
Cumulative data of all experiments in (B/C); N=[7;7;7;5] and [6;4;5;4] for the time points day 787 
[3;8;15;range [30-40]] for (B) and (C), respectively, with error bars representing SD; multiple 788 
t-tests with Holm-Sidak correction for multiple comparisons, p-values shown if<0.05.  789 
 790 
Figure 5. Ex vivo tissue analysis of transplanted tissues. | (A) Ex vivo radioactivity analysis of 791 
harvested tissues. Mouse skin was harvested from a region above lower spine. Human skin grafts 792 
were compared to mouse skin from the same animal using paired t-tests. No Treg/PBMC only 793 
control: not significant over all time points (p=0.2526), solid vs. dashed black lines; BRG 794 
without Gr-1+ cells: not significant for early time points (p=0.4850) but significant on day 40 795 
(p=0.0309), solid vs. dashed pink lines; BRG with Gr-1+ cells present: significant over all time 796 
points (p=0.0016), solid vs. dashed blue lines. Human skin grafts from different animal cohorts 797 
were compared using unpaired ANOVA either on day 8 or day 40 with p-values shown within 798 
panel (A). Cumulative data; N=2 (days 3, 15) and N=4 (days 8, 40); error bars are SEM. (B-E) 799 
Immunofluorescence staining of harvested tissues with anti-human CD3 (red in merged images) 800 
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and anti-FOXP3 antibodies (green in merged images). Indicated times refer to days after 801 
adoptive Treg transfer as in Fig.4. (B/Black) untreated mice that received only PBMCs or 802 
(C/white) no cells (saline only). (D/pink) Representative confocal micrographs of Gr-1+ cell-803 
depleted mice, which received PBMC and NIS-GFP+ Tregs. (E/blue) experiments as in (C) but 804 
performed in BRG mice without Gr-1+ cell depletion. CD3 staining is indicative of administered 805 
PBMC-derived human T cells and Tregs, while FOXP3 staining identified administered human 806 
Tregs only. Scale bars are 100 µm.  807 
 808 
Figure 6. In vitro Treg migration assay. | (A) Trans-well migration assay (3 µm pores) of 809 
human Tregs from five different donors (top chamber). The bottom chambers contained growth 810 
medium without or with chemokines CCL17/CCL22; PTX indicates that Tregs were pre-treated 811 
with pertussis toxin. (B) Cumulative data of (A) showing mean±SD. 2-way ANOVA revealed 812 
significant differences (p<0.0001); migration increased significantly with CCL17/CCL22 813 
(p=0.0001; with Dunnett’s multiple comparisons test) compared to other conditions. (C) Trans-814 
well migration assay as in (A) but with the bottom chambers containing the following purified 815 
murine cells: none; neutrophils; monocytes; neutrophils+monocytes. Data are grouped per donor. 816 
(D) Cumulative data of (C) showing mean±SD. 2-way ANOVA revealed significant differences 817 
with different cells admixed (p=0.0112); Dunnett’s multiple comparisons test revealed 818 
significant differences for each cell admixture when compared with media only (see p-values 819 
within figure panel). (E/F) Data from same experiments as in (C/D) but Tregs were pre-treated 820 
with pertussis toxin (PTX). No significant differences were found between the groups by the 821 
same statistical tests as in (C/D).  822 
 823 
<<<End of Main Manuscript>>> 824 
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eTOC Synopsis 
Adoptive regulatory T-cell (Treg) therapy emerges as a treatment in organ transplantation, 
yet Treg in vivo distribution and persistence remain elusive. 
Jacob et al developed a non-invasive long-term Tregs therapy tracking method and validated 
it in humanized models of transplantation. Adaption for future clinical Treg therapy imaging 
is straightforward. 
 
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
